Hong Kong-Listed China Biotech Company New Horizon Health Chairman & CEO Zhu Yeqing Resigns and Removed by Board as Executive Director, CFO and Auditor Deloitte Resigned Earlier in 2024 after Short Seller Claims New Horizon Health Inflated 2022 Sales, Share Trading Suspended Since 26th March 2024, New Horizon Health IPO on Hong Kong Exchange in 2021 with Share Price Increasing +185% on Day 1 Trading to $3.9 Billion Market Value
2nd January 2025 | Hong Kong
Hong Kong-listed China biotech company New Horizon Health Chairman & CEO Zhu Yeqing has resigned (Chairman & CEO) and removed by the Board as Executive Director (30/12/24). Earlier in 2024, New Horizon Health Chief Financial Officer (CFO) and auditor Deloitte had resigned after a short seller had claimed New Horizon Health inflated 2022 sales. New Horizon Health share trading had been suspended since 26th March 2024. New Horizon Health IPO on Hong Kong Exchange (HKEX) in 2021, with share price increasing +185% on day 1 trading to $3.9 billion market value (HKD 31 billion). New Horizon Health – Founded in 2015, New Horizon Health is a cancer screening market leader, focusing on the design, development and commercialization of cancer screening tests. The company’s vision is to prevent and cure cancer by screening and early detection. The company markets its tests through multiple channels, including hospitals, health checkup centers, insurance companies, pharmacy and online channels. The company has built a portfolio of 71 patents and patent applications globally.
“ Hong Kong-Listed China Biotech Company New Horizon Health Chairman & CEO Zhu Yeqing Resigns and Removed by Board as Executive Director, CFO and Auditor Deloitte Resigned Earlier in 2024 after Short Seller Claims New Horizon Health Inflated 2022 Sales, Share Trading Suspended Since 26th March 2024, New Horizon Health IPO on Hong Kong Exchange in 2021 with Share Price Increasing +185% on Day 1 Trading to $3.9 Billion Market Value “
Hong Kong-Listed China Biotech Company New Horizon Health Chairman & CEO Zhu Yeqing Resigns and Removed by Board as Executive Director, CFO and Auditor Deloitte Resigned Earlier in 2024 after Short Seller Claims New Horizon Health Inflated 2022 Sales, Share Trading Suspended Since 26th March 2024, New Horizon Health IPO on Hong Kong Exchange in 2021 with Share Price Increasing +185% on Day 1 Trading to $3.9 Billion Market Value
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit